Applied BioMath

Applied BioMath utilizes mathematical modeling and simulation to provide quantitative insights for drug research and development. The company uses a Model-Aided Drug Invention (MADI) approach that utilizes proprietary algorithms and software to provide predictive insights and assistance to biotechnology and pharmaceutical companies during all stages of drug development. The company was founded in 2013 by Joshua Apgar and current CEO John M. Burke. It is headquartered in Concord, Massachusetts, with an additional office in Oakland, California.

The company aims to expedite and de-risk drug research and development through its platform and services. Applied BioMath works with companies from early research to clinical trials to help them choose the right mathematical and scientific approach for their projects. They collaborate with their partners to create customized mechanistic and mathematical models for each project to allow for model-driven, data-informed decision-making. The company's web-based application, Applied BioMath Assess, is designed to simulate pre-built models in various therapeutic modalities and disease areas to help with target selection, project clinical dose requirements, and identify areas of program risk.

The company offers support in early research and discovery, preclinical studies, and clinical studies through their services which include: target ID and validation, early feasibility assessments, lead ID screening and optimization, clinical candidate selection, study design, dose prediction, IND preparation, and more.

The company aims to expedite and de-risk drug research and development through its platform and services. Applied BioMath works with companies from early research to clinical trials to help them choose the right mathematical and scientific approach for their projects. They collaborate with their partners to create customized mechanistic and mathematical models for each project to allow for model-driven, data-informed decision-making. The company's web-based application, Applied BioMath Assess, is designed to simulate pre-built models in various therapeutic modalities and disease areas to help with target selection, project clinical dose requirements, and identify areas of program risk.

The company offers support in early research and discovery, pre-clinical studies, and clinical studies through its services, which include target ID and validation, early feasibility assessments, lead ID screening and optimization, clinical candidate selection, study design, dose prediction, and IND preparation.

Applied BioMath utilizes mathematical modeling and simulation forto provide quantitative insights for drug research and development. The company uses a Model-Aided Drug Invention (MADI) approach that utilizes proprietary algorithms and software to provide predictive insights and assistance to biotechnology and pharmaceutical companies during all stages of drug development. The company was founded in 2013 by Joshua Apgar and current CEO John M. Burke. It is headquartered in Concord, Massachusetts with an additional office in Oakland, California.

Applied BioMath utilizes mathematical modeling and simulation for quantitative insights for drug research and development. The company uses a Model-Aided Drug Invention (MADI) approach that utilizes proprietary algorithms and software to provide predictive insights and assistance to biotechnology and pharmaceutical companies during all stages of drug development. The company was founded in 2013 by Joshua Apgar and current CEO John M. Burke. It is headquartered in Concord, Massachusetts with an additional office in Oakland, California.

The company aims to expedite and de-risk drug research and development through its platform and services. Applied BioMath works with companies from early research to clinical trials to help them choose the right mathematical and scientific approach for their projects. They collaborate with their partners to create customized mechanistic and mathematical models for each project to allow for model-driven, data-informed decision-making. The company's web-based application, Applied BioMath Assess, is designed to simulate pre-built models in various therapeutic modalities and disease areas to help with target selection, project clinical dose requirements, and identify areas of program risk.

The company offers support in early research and discovery, preclinical studies, and clinical studies through their services which include: target ID and validation, early feasibility assessments, lead ID screening and optimization, clinical candidate selection, study design, dose prediction, IND preparation, and more.